TALEN

TALEN1-gba1

ID

ZDB-TALEN-160129-1

Name

TALEN1-gba1

Previous Names

TALEN1-gba

Target

gba1 (1)

Target Sequence 1

5' - TCTGTACCCTGATTACTT - 3'

Target Sequence 2

5' - TGGACTCCACCCAGCGCAT - 3'

Disclaimer

Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.

Note

None

Genome Resources

None

Target Location

Constructs

No data available

Genomic Features

Genomic Feature	Affected Genomic Regions
sh391	gba1

Expression

Gene expression in Wild Types + TALEN1-gba1

No data available

Phenotype

Phenotype resulting from TALEN1-gba1

No data available

Phenotype of all Fish created by or utilizing TALEN1-gba1

Phenotype	Fish	Conditions	Figures
optic tectum microglial cell increased amount, abnormal	gba1^sh391/sh391	standard conditions	Fig. 4 from Watson et al., 2019
brain ubiquinol-cytochrome-c reductase activity decreased process quality, abnormal	gba1^sh391/sh391	standard conditions	Fig. 6. from Keatinge et al., 2023
brain sphingosine increased amount, abnormal	gba1^sh391/sh391	standard conditions	Fig. 3. from Keatinge et al., 2023
brain glucosylceramide increased amount, abnormal	gba1^sh391/sh391	standard conditions	Fig. 3. from Keatinge et al., 2023
retina microglial cell increased amount, abnormal	gba1^sh391/sh391	standard conditions	Fig. 4. from Keatinge et al., 2023
brain tnfb expression increased amount, abnormal	gba1^sh391/sh391	standard conditions	Fig. 1, Fig. 3 from Watson et al., 2019
brain cytochrome-c oxidase activity decreased process quality, abnormal	gba1^sh391/sh391	standard conditions	Fig. 6. from Keatinge et al., 2023
microglial cell increased accumulation cerebellum, abnormal	gba1^sh391/sh391	standard conditions	Fig. 4 from Watson et al., 2019
brain membrane lipid catabolic process increased process quality, abnormal	gba1^sh391/sh391	standard conditions	Fig. 6. from Keatinge et al., 2023
brain beta-D-galactosyl-(1->4)-beta-D-glucosyl-(1<->1)-ceramide increased amount, abnormal	gba1^sh391/sh391	standard conditions	Fig. 3. from Keatinge et al., 2023
whole organism viability, abnormal	gba1^sh391/sh391	standard conditions	Fig. 5. from Keatinge et al., 2023
cerebellum microglial cell increased amount, abnormal	gba1^sh391/sh391	standard conditions	Fig. 4 from Watson et al., 2019
brain ceramide increased amount, abnormal	gba1^sh391/sh391	standard conditions	Fig. 3. from Keatinge et al., 2023
microglial cell increased accumulation optic tectum, abnormal	gba1^sh391/sh391	standard conditions	Fig. 4 from Watson et al., 2019
brain cxcl8b.1 expression increased amount, abnormal	gba1^sh391/sh391	standard conditions	Fig. 1, Fig. 3 from Watson et al., 2019
brain cxcl8a expression increased amount, abnormal	gba1^sh391/sh391	standard conditions	Fig. 1, Fig. 3 from Watson et al., 2019
whole organism swimming behavior decreased process quality, abnormal	gba1^sh391/sh391 (AB/TL)	standard conditions	Fig. 4 from Wolińska-Nizioł et al., 2022
glucosylceramidase activity decreased process quality, abnormal	gba1^sh391/sh391 (TL)	standard conditions	Fig. 1 from Keatinge et al., 2015
thymus macrophage morphology, abnormal	gba1^sh391/sh391 (TL)	standard conditions	Fig. 5 from Keatinge et al., 2015
brain autophagosome increased amount, abnormal	gba1^sh391/sh391 (TL)	standard conditions	Fig. 8 from Keatinge et al., 2015
CNS neuron (sensu Vertebrata) inclusion body increased amount, abnormal	gba1^sh391/sh391 (TL)	standard conditions	Fig. 7 from Keatinge et al., 2015
caudal periventricular hypothalamus dopaminergic neuron decreased amount, abnormal	gba1^sh391/sh391 (TL)	standard conditions	Fig. 7 from Keatinge et al., 2015
brain mitochondrion decreased functionality, abnormal	gba1^sh391/sh391 (TL)	standard conditions	Fig. 8 from Keatinge et al., 2015
tectal ventricle macrophage increased size, abnormal	gba1^sh391/sh391 (TL)	standard conditions	Fig. 5 from Keatinge et al., 2015
brain hexosaminidase activity increased process quality, abnormal	gba1^sh391/sh391 (TL)	standard conditions	Fig. 3 from Keatinge et al., 2015
macrophage increased accumulation tectal ventricle, abnormal	gba1^sh391/sh391 (TL)	standard conditions	Fig. 5 from Keatinge et al., 2015
brain chitinase activity increased process quality, abnormal	gba1^sh391/sh391 (TL)	standard conditions	Fig. 3 from Keatinge et al., 2015
brain ubiquinol-cytochrome-c reductase activity decreased process quality, abnormal	gba1^sh391/sh391 (TL)	standard conditions	Fig. 8 from Keatinge et al., 2015
whole organism decreased life span, abnormal	gba1^sh391/sh391 (TL)	standard conditions	text only from Keatinge et al., 2015
whole organism dead, abnormal	gba1^sh391/sh391 (TL)	standard conditions	text only from Keatinge et al., 2015
brain glial cell projection retracted, abnormal	gba1^sh391/sh391 (TL)	standard conditions	Fig. 5 from Keatinge et al., 2015
microglial cell increased accumulation brain, abnormal	gba1^sh391/sh391 (TL)	standard conditions	Fig. 5 from Keatinge et al., 2015
brain sncb expression decreased amount, abnormal	gba1^sh391/sh391 (TL)	standard conditions	Fig. 7 from Keatinge et al., 2015
brain macrophage morphology, abnormal	gba1^sh391/sh391 (TL)	standard conditions	Fig. 5 from Keatinge et al., 2015
brain macrophage increased amount, abnormal	gba1^sh391/sh391 (TL)	standard conditions	Fig. 5 from Keatinge et al., 2015
brain cytochrome-c oxidase activity decreased process quality, abnormal	gba1^sh391/sh391 (TL)	standard conditions	Fig. 8 from Keatinge et al., 2015
swimming decreased process quality, abnormal	gba1^sh391/sh391 (TL)	standard conditions	Fig. 4 from Keatinge et al., 2015
liver macrophage increased amount, abnormal	gba1^sh391/sh391 (TL)	standard conditions	Fig. 5 from Keatinge et al., 2015
liver macrophage morphology, abnormal	gba1^sh391/sh391 (TL)	standard conditions	Fig. 5 from Keatinge et al., 2015
sphingolipid metabolic process disrupted, abnormal	gba1^sh391/sh391 (TL)	standard conditions	Fig. 2 from Keatinge et al., 2015
spinal cord curved, abnormal	gba1^sh391/sh391 (TL)	standard conditions	Fig. 3 from Keatinge et al., 2015
caudal tuberculum dopaminergic neuron decreased amount, abnormal	gba1^sh391/sh391 (TL)	standard conditions	Fig. 7 from Keatinge et al., 2015
brain microglial cell circular, abnormal	gba1^sh391/sh391 (TL)	standard conditions	Fig. 5 from Keatinge et al., 2015
thymus macrophage increased amount, abnormal	gba1^sh391/sh391 (TL)	standard conditions	Fig. 5 from Keatinge et al., 2015
brain mir155 expression increased amount, abnormal	gba1^sh391/sh391; sh425Tg (TL)	standard conditions	Fig. 6 from Keatinge et al., 2015
microglial cell activation increased occurrence, abnormal	gba1^sh391/sh391; sh425Tg (TL)	standard conditions	Fig. 6 from Keatinge et al., 2015
microglial cell vacuole increased amount, abnormal	gba1^sh391/sh391; sh425Tg (TL)	standard conditions	Fig. 6 from Keatinge et al., 2015
microglial cell spherical, abnormal	gba1^sh391/sh391; sh425Tg (TL)	standard conditions	Fig. 6 from Keatinge et al., 2015
whole organism mir155 expression increased amount, abnormal	gba1^sh391/sh391; sh425Tg (TL)	standard conditions	Fig. 6 from Keatinge et al., 2015
brain cxcl8a expression increased amount, abnormal	gba1^sh391/sh391; mir155^sh610/sh610	standard conditions	Fig. 3 from Watson et al., 2019
microglial cell increased accumulation cerebellum, abnormal	gba1^sh391/sh391; mir155^sh610/sh610	standard conditions	Fig. 4 from Watson et al., 2019
cerebellum microglial cell increased amount, abnormal	gba1^sh391/sh391; mir155^sh610/sh610	standard conditions	Fig. 4 from Watson et al., 2019
optic tectum microglial cell increased amount, abnormal	gba1^sh391/sh391; mir155^sh610/sh610	standard conditions	Fig. 4 from Watson et al., 2019
brain tnfb expression increased amount, abnormal	gba1^sh391/sh391; mir155^sh610/sh610	standard conditions	Fig. 3 from Watson et al., 2019
brain cxcl8b.1 expression increased amount, abnormal	gba1^sh391/sh391; mir155^sh610/sh610	standard conditions	Fig. 3 from Watson et al., 2019
microglial cell increased accumulation optic tectum, abnormal	gba1^sh391/sh391; mir155^sh610/sh610	standard conditions	Fig. 4 from Watson et al., 2019
brain sphinganine amount, exacerbated	gba1^sh391/sh391; smpd1^sh696/sh696	standard conditions	Fig. 3. from Keatinge et al., 2023
brain membrane lipid catabolic process process quality, ameliorated	gba1^sh391/sh391; smpd1^sh696/sh696	standard conditions	Fig. 6. from Keatinge et al., 2023
brain glucosylceramide amount, exacerbated	gba1^sh391/sh391; smpd1^sh696/sh696	standard conditions	Fig. 3. from Keatinge et al., 2023
brain beta-D-galactosyl-(1->4)-beta-D-glucosyl-(1<->1)-ceramide amount, exacerbated	gba1^sh391/sh391; smpd1^sh696/sh696	standard conditions	Fig. 3. from Keatinge et al., 2023
brain sphingosine increased amount, abnormal	gba1^sh391/sh391; smpd1^sh696/sh696	standard conditions	Fig. 3. from Keatinge et al., 2023
brain ubiquinol-cytochrome-c reductase activity decreased process quality, abnormal	gba1^sh391/sh391; smpd1^sh696/sh696	standard conditions	Fig. 6. from Keatinge et al., 2023
brain sphingomyelin increased amount, abnormal	gba1^sh391/sh391; smpd1^sh696/sh696	standard conditions	Fig. 3. from Keatinge et al., 2023
whole organism viability, ameliorated	gba1^sh391/sh391; smpd1^sh696/sh696	standard conditions	Fig. 5. from Keatinge et al., 2023
brain cytochrome-c oxidase activity process quality, ameliorated	gba1^sh391/sh391; smpd1^sh696/sh696	standard conditions	Fig. 6. from Keatinge et al., 2023
brain ceramide amount, exacerbated	gba1^sh391/sh391; smpd1^sh696/sh696	standard conditions	Fig. 3. from Keatinge et al., 2023
brain NADH dehydrogenase (ubiquinone) activity process quality, ameliorated	gba1^sh391/sh391; smpd1^sh696/sh696	standard conditions	Fig. 6. from Keatinge et al., 2023
retina microglial cell increased amount, abnormal	gba1^sh391/sh391; smpd1^sh696/sh696	standard conditions	Fig. 4. from Keatinge et al., 2023
whole organism swimming behavior decreased process quality, abnormal	gba1^sh391/sh391; tollip^{waw401/waw401} (AB/TL)	standard conditions	Fig. 4 from Wolińska-Nizioł et al., 2022

Citations